XML 46 R17.htm IDEA: XBRL DOCUMENT v3.25.4
Information about Components of Equity
12 Months Ended
Jun. 30, 2025
Information about Components of Equity [Abstract]  
INFORMATION ABOUT COMPONENTS OF EQUITY
11.INFORMATION ABOUT COMPONENTS OF EQUITY

 

Capital issued

 

As described in Note 1 – The Group’s business reorganization and general information – “The Bioceres Group Business Combination Agreement” and in note 6 – Acquisitions and other significant transactions – “Bioceres Group, Nutrecon, Gentle Tech and Moolec Science business combination”, the Company completed a reverse acquisition on June 16, 2025, whereby Moolec Science SA (“the Legal Acquirer”) legally acquired Bioceres Group, Nutrecon and Gentle Tech (“the Legal Acquirees”). For accounting purposes, however, Bioceres Group was identified as the accounting acquirer in accordance with IFRS 3 Business Combinations. As a result, the consolidated financial statements represent a continuation of the financial statements of the accounting acquirer, except for the capital structure, which is that of the legal acquirer. Following the reverse acquisition, Share Capital reflects the share capital of Moolec Science SA, including the shares issued to the former shareholders of the accounting acquirer as consideration for the transaction.

 

The number of shares issued as of June 30, 2025, 2024 and 2023 is the following:

 

Year ended  Class  Number of
Shares
   Nominal Value   Subscribed capital 
06/30/2023  Ordinary   5,301,700   $0.10    5,301,700   $530,170 
06/30/2024  Ordinary   5,983,687   $0.10    5,983,687   $598,369 
06/30/2025  Ordinary   10,891,761   $0.10    10,891,761   $1,089,176 

 

Holders of the ordinary shares are entitled to one vote for each ordinary share.

 

Reserves

 

Foreign currency translation reserve

 

The translation reserve comprises all foreign currency differences arising from the translation of the financial statements of foreign operations.

Revaluation of PP&E and effect of tax rate change

 

The revaluation reserve relates to the revaluation of Land and buildings, prior to the BIOX deconsolidation, as mentioned in note 4.8 – Property, plant and equipment, net of income tax effect.

 

Own shares held

 

The reserve of the Company´s own shares held comprises the cost of the Company’s shares held by the Group. At June 30, 2025, the Group held 80,370 of the Company’s shares. (2024: 60,083).

 

Share premium

 

Share premium represents the excess of the consideration received over the par value of shares issued, net of directly attributable transaction costs, and is presented within equity in accordance with IAS 32.

 

Non-controlling interests

 

The subsidiaries whose non-controlling interest is significant as of June 30, 2025 and 2024 are:

 

Name  06/30/2025   06/30/2024 
         
Bioceres S.A.   10.07%   26.53%
Bioceres Crop Solutions (*)   
-
    72.67%

 

Below is a detail of the summarized financial information of Bioceres S.A., prepared in accordance with IFRS, and modified due to fair value adjustments at the acquisition date and differences in accounting policies. The information is presented prior to eliminations between that subsidiary and other Group companies.

 

(*)Bioceres Crop Solutions ceased to be a subsidiary in June 24, 2025.

 

Bioceres S.A.

 

Summary financial statements:            

 

   06/30/2025   06/30/2024 
         
Current assets   19,390,689    37,499,373 
Non-current assets   (12,909,646)   78,742,912 
Total assets   6,481,043    116,242,285 
           
Current liabilities   97,284,715    47,526,407 
Non-current liabilities   238,458    14,689,742 
Total liabilities   97,523,173    62,216,149 
           
Total equity   (91,042,130)   54,026,136 
           
Total liabilities and equity   6,481,043    116,242,285 

Summary statements of comprehensive income or loss

 

   06/30/2025   06/30/2024   06/30/2023 
             
Revenues   780,952    1,422,707    1,074,655 
Government grants   3,412    197,519    49,185 
Gross margin   784,364    1,620,226    1,123,840 
                
Research and development expenses   (223,688)   (239,446)   (175,737)
Selling, general and administrative expenses   (2,275,441)   (3,248,643)   (3,287,433)
Share of profit or loss of subsidiaries   (33,367,101)   (3,285,724)   5,287,879 
Share of profit or loss of joint ventures and associates   (285)   (2,592)   (3,917)
Other income / (loss), net   (56,484,792)   11,126    249,372 
Operating loss   (91,566,943)   (5,145,053)   3,194,004 
                
Financial results   2,891,781    (1,128,752)   (4,327,324)
Loss before taxes   (88,675,162)   (6,273,805)   (1,133,320)
                
Income tax (expense) / benefit   (1,653,797)   471,416    (463,175)
Result for the year   (90,328,959)   (5,802,389)   (1,596,495)
                
Revaluation of property, plant and equipment, net of tax             (434,390)
Foreign exchange differences on translation of foreign operations   (5,467,311)   (3,865,328)   (5,182,181)
Total comprehensive result   (95,796,270)   (9,667,717)   (7,213,066)

 

Bioceres Crop Solutions

 

Summary financial statements:

 

   06/30/2025   06/30/2024 
         
Current assets   
    -
    408,668,037 
Non-current assets   
-
    441,960,310 
Total assets   
-
    850,628,347 
           
Current liabilities   
-
    329,505,846 
Non-current liabilities   
-
    171,558,140 
Total liabilities   
-
    501,063,986 
           
Total equity   
-
    349,564,361 
          
Total liabilities and equity   
-
    850,628,347 

Summary statements of comprehensive income or loss

 

   06/30/2025   06/30/2024   06/30/2024 
             
Revenues   333,343,987    464,828,548    419,446,439 
Initial recognition and changes in the fair value of biological assets at the point of harvest   1,764,863    (45,746)   610,554 
                
Cost of sales   (203,424,872)   (278,221,812)   (235,457,053)
Changes in the net realizable value of agricultural products after harvest   (1,541,204)   (2,385,069)   (4,351,433)
Research and development expenses   (14,914,822)   (17,183,041)   (15,345,315)
Selling, general and administrative expenses   (123,113,572)   (123,690,910)   (113,002,747)
Share of profit or loss of joint ventures and associates   (1,126,312)   4,049,508    1,198,628 
Other income or expenses, net   6,775,970    (1,498,555)   1,084,892 
Operating (loss) / profit   (2,235,962)   45,852,923    54,183,965 
                
Financial results   (55,335,675)   (34,785,325)   (35,078,018)
(Loss) / profit before taxes   (57,571,637)   11,067,598    19,105,947 
                
Income tax   (1,273,616)   (3,778,615)   1,068,652 
Result for the year   (58,845,253)   7,288,983    20,174,599 
                
Foreign exchange differences on translation of foreign operations   (714,251)   (787,354)   631,500 
Revaluation of property, plant and equipment, net of tax   
-
    
-
    (1,467,349)
Total comprehensive result   (59,559,504)   6,501,629    19,338,750